DaVita Inc. (NYSE:DVA) Shares Sold by Axa S.A.

Axa S.A. trimmed its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 91.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,381 shares of the company's stock after selling 24,165 shares during the period. Axa S.A.'s holdings in DaVita were worth $356,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of DVA. Mercer Global Advisors Inc. ADV grew its holdings in DaVita by 21.7% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 12,404 shares of the company's stock worth $1,855,000 after buying an additional 2,212 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec boosted its position in DaVita by 533.1% during the 4th quarter. Caisse DE Depot ET Placement DU Quebec now owns 70,269 shares of the company's stock worth $10,509,000 after acquiring an additional 59,169 shares during the period. Comerica Bank grew its stake in shares of DaVita by 9.9% in the fourth quarter. Comerica Bank now owns 30,299 shares of the company's stock worth $4,531,000 after purchasing an additional 2,737 shares in the last quarter. Kapitalo Investimentos Ltda bought a new stake in shares of DaVita during the fourth quarter valued at about $159,000. Finally, Schonfeld Strategic Advisors LLC lifted its holdings in DaVita by 91.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 20,915 shares of the company's stock worth $3,128,000 after purchasing an additional 9,974 shares during the period. Institutional investors own 90.12% of the company's stock.

DaVita Stock Performance

Shares of NYSE DVA opened at $143.62 on Friday. DaVita Inc. has a 52-week low of $131.44 and a 52-week high of $179.60. The stock has a market capitalization of $11.04 billion, a price-to-earnings ratio of 13.37, a PEG ratio of 1.07 and a beta of 1.14. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. The stock's fifty day simple moving average is $145.85 and its 200 day simple moving average is $153.94.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. As a group, sell-side analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. StockNews.com upgraded shares of DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. Cowen restated a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. Barclays boosted their price objective on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 target price on DaVita in a research note on Friday, February 21st. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $166.33.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.